Romidepsin in peripheral and cutaneous T‐cell lymphoma: mechanistic implications from clinical and correlative data

Susan E Bates, Robin Eisch, Alexander Ling, Douglas Rosing, Maria Turner, Stefania Pittaluga, H Miles Prince, Mark H Kirschbaum, Steven L Allen, Jasmine Zain, Larisa J Geskin, David Joske, Leslie Popplewell, Edward W Cowen, Elaine S Jaffe, Jean Nichols, Sally Kennedy, Seth M Steinberg, David J Liewehr, Louise C Showe, Caryn Steakley, John Wright, Tito Fojo, Thomas Litman, Richard L Piekarz

Romidepsin is an epigenetic agent approved for the treatment of patients with cutaneous or peripheral T-cell lymphoma (CTCL and PTCL). Here we report data in all patients treated on the National Cancer Institute 1312 trial, demonstrating long-term disease control and the ability to retreat patients relapsing off-therapy. In all, 84 patients with CTCL and 47 with PTCL were enrolled. Responses occurred early, were clinically meaningful and of very long duration in some cases. Notably, patients with PTCL receiving romidepsin as third-line therapy or later had a comparable response rate (32%) of similar duration as the total population (38%). Eight patients had treatment breaks of 3·5 months to 10 years; in four of six patients, re-initiation of treatment led to clear benefit. Safety data show slightly greater haematological and constitutional toxicity in PTCL. cDNA microarray studies show unique individual gene expression profiles, minimal overlap between patients, and both induction and repression of gene expression that reversed within 24 h. These data argue against cell death occurring as a result of an epigenetics-mediated gene induction programme. Together this work supports the safety and activity of romidepsin in T-cell lymphoma, but suggests a complex mechanism of action.